Related references
Note: Only part of the references are listed.PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome
Changye Zou et al.
ANNALS OF SURGERY (2009)
[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1
Victoria S. Warbey et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Expression and significance of EGFR in malignant peripheral nerve sheath tumor
Daniel Keizman et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours
Irene Bottillo et al.
JOURNAL OF PATHOLOGY (2009)
It Takes a (Dysfunctional) Village to Raise a Tumor
Karlyne M. Reilly et al.
CELL (2008)
Differential expression of angiogenic factors in peripheral nerve sheath tumors
Junji Wasa et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization
Kiran K. Mantripragada et al.
CLINICAL CANCER RESEARCH (2008)
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Jaclyn LoPiccolo et al.
DRUG RESISTANCE UPDATES (2008)
Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1 - A randomized controlled trial
Lianne C. Krab et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Neurofibromin as a regulator of melanocyte development and differentiation
Ganesh Diwakar et al.
JOURNAL OF CELL SCIENCE (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin
Jonathan W. Wojtkowiak et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations
Stephen R. Grobmyer et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells
Grazia Ambrosini et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
Gunnar Johansson et al.
MOLECULAR CANCER THERAPEUTICS (2008)
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy
Nikola Holtkamp et al.
NEURO-ONCOLOGY (2008)
Malignant Peripheral Nerve Sheath Tumors
Gaurav Gupta et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2008)
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors
Hussein Tawbi et al.
ONCOLOGIST (2008)
A 10 year review of benign and malignant peripheral nerve sheath tumors in a single center: Clinical and radiographic features can help to differentiate benign from malignant lesions
Dominic Furniss et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2008)
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Steven J. Harper et al.
NATURE REVIEWS CANCER (2008)
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and mnk-mediated eukaryotic translation initiation factor 4E phosphorylation
Xuerong Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors
Nikola Holtkamp et al.
NEOPLASIA (2007)
Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB
Mikiko Aoki et al.
LABORATORY INVESTIGATION (2007)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model
Yonatan Y. Mahller et al.
MOLECULAR THERAPY (2007)
Markers of angiogenesis and clinical features in patients with sarcoma
Steven DuBois et al.
CANCER (2007)
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
N. van Zandwijk et al.
ANNALS OF ONCOLOGY (2007)
Radiation induced peripheral nerve tumors: case series and review of the literature
Gelareh Zadeh et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1
Joshua T. Dilworth et al.
BIOCHEMICAL PHARMACOLOGY (2006)
The value of magnetic resonance imaging in the differentiation between malignant peripheral nerve-sheath tumors and non-neurogenic malignant soft-tissue tumors
B. H. Van Herendael et al.
SKELETAL RADIOLOGY (2006)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
Pathophysiology of neurofibromatosis type 1
Amy Theos et al.
ANNALS OF INTERNAL MEDICINE (2006)
Second primary tumors in neurofibromatosis I patients treated for optic glioma: Substantial risks after radiotherapy
Saba Sharif et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants
YY Mahller et al.
PEDIATRIC BLOOD & CANCER (2006)
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity
N Holtkamp et al.
CARCINOGENESIS (2006)
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas
BC Widemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines
RR Mattingly et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Malignant peripheral nerve sheath tumors - Prognostic factors and survival in a series of patients treated at a single institution
Matteo Anghileri et al.
CANCER (2006)
Farnesyl transferase inhibitors
AD Basso et al.
JOURNAL OF LIPID RESEARCH (2006)
Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group
M Carli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
DR D'Adamo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling
S Roy et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
An expanding role for mTOR in cancer
DA Guertin et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Association between benign and malignant peripheral nerve sheath tumors in NF1
T Tucker et al.
NEUROLOGY (2005)
The NF1 tumor suppressor critically regulates TSC2 and mTOR
CM Johannessen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB
I Dang et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis
BC Ling et al.
CANCER CELL (2005)
Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
A Gschwind et al.
NATURE REVIEWS CANCER (2004)
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors
N Holtkamp et al.
ACTA NEUROPATHOLOGICA (2004)
Survival data for patients with malignant schwannoma
DV Cashen et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2004)
Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours
S Cardona et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2003)
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia
MA Morgan et al.
LEUKEMIA (2003)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang et al.
LEUKEMIA (2003)
Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression
WP Su et al.
GLIA (2003)
Elevated risk for MPNST in NF1 microdeletion patients
T De Raedt et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1(+/-) mast cells
FC Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells
S Donovan et al.
CANCER CELL (2002)
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms
A Perry et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial
ML Hensley et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors
C Mawrin et al.
VIRCHOWS ARCHIV (2002)
Neurofibromas in NF1: Schwann cell origin and role of tumor environment
Y Zhu et al.
SCIENCE (2002)
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
DGR Evans et al.
JOURNAL OF MEDICAL GENETICS (2002)
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis
WWL Wong et al.
LEUKEMIA (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Hyperactivation of p21ras and the hematopoietic-specific Rho GTPase Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro
DA Ingram et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors
A Perry et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Developmental roles of platelet-derived growth factors
C Betsholtz et al.
BIOESSAYS (2001)
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors
S Birindelli et al.
LABORATORY INVESTIGATION (2001)
Connecting signaling and cell cycle progression in growth factor-stimulated cells
SM Jones et al.
ONCOGENE (2000)
Epidermal growth factor receptor expression in. neurofibromatosis type 1-related tumors and NF1 animal models
JE DeClue et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
E Raymond et al.
DRUGS (2000)
Loss of neurofibromin is associated with activation of Ras/MAPK and PI3-K/Akt signaling in a neurofibromatosis 1 astrocytoma
N Lau et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2000)
Share Paper
